期刊
BLOOD
卷 119, 期 17, 页码 4083-4090出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-02-409763
关键词
-
类别
资金
- US Public Health Service from National Cancer Institute (NCI) [U24-CA76518, 5U01HL069294]
- National Heart, Lung, and Blood Institute (NHLBI) [5U01HL069294]
- National Institute of Allergy and Infectious Diseases
- Health Resources and Services Administration [HHSH234200637015C]
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- AABB (National Blood Foundation)
- Allos Inc
- Amgen Inc
- Astellas Pharma US Inc
- Be the Match Foundation
- Biogen IDEC
- Bio-Marin Pharmaceutical Inc
- Biovitrum AB
- BloodCenter of Wisconsin
- Blue Cross and Blue Shield Association
- Bone Marrow Foundation
- Buchanan Family Foundation
- CaridianBCT
- Celgene Corporation
- CellGenix GmbH
- Children's Leukemia Research Association
- ClinImmune Labs
- CTI Clinical Trial and Consulting Services
- Eisai Inc
- Genentech Inc
- Genzyme Corporation
- Histogenetics Inc
- HKS Medical Information Systems
- Hospira Inc
- Kirin Brewery Co Ltd
- The Leukemia & Lymphoma Society
- Merck Company
- Medical College of Wisconsin
- Millennium Pharmaceuticals Inc
- Miller Pharmacal Group
- Milliman USA Inc
- Miltenyi Biotec Inc
- National Marrow Donor Program
- Nature Publishing Group
- Novartis Oncology
- Oncology Nursing Society
- Osiris Therapeutics Inc
- Otsuka America Pharmaceutical Inc
- Pall Life Sciences
- Pfizer Inc
- Schering Corporation
- Sigma-Tau Pharmaceuticals
- Soligenix Inc
- StemCyte Inc
- StemSoft Software Inc
- Sysmex America Inc
- THERAKOS Inc
- Vidacare Corporation
- ViraCor Laboratories
- ViroPharma Inc
- Wellpoint Inc
Tyrosine kinase inhibitors (TKIs) and reduced intensity conditioning (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the therapeutic strategy for chronic myelogenous leukemia (CML) patients. We analyzed post-HCT outcomes of 306 CML patients reported to the Center for International Blood and Marrow Transplant Research aged 40 years and older undergoing RIC/NMA HCT from 2001 to 2007: 117 (38%) aged 40 to 49 years, 119 (39%) 50 to 59 years, and 70 (23%) 60 years or older. The majority (74%) had treatment with imatinib before HCT. At HCT, most patients aged 40 to 49 years were in chronic phase (CP) 1 (74%), compared with 31% aged 60 years or older. Siblings were donors for 56% aged 40 to 49 years; older cohorts had more unrelated donors. The majority received peripheral blood grafts and RIC across all age groups. 3 year overall survival (54%, 52%, and 41%), day + 100 grade II-IV acute GVHD (26%, 32%, and 32%), chronic GVHD (58%, 51%, and 43%), and 1-year treatment-related mortality (18%, 20%, and 13%) were similar across ages. The 3-year relapse incidence (36%, 43%, and 66%) and disease-free survival (35%, 32%, and 16%) were inferior in the oldest cohort. Importantly, for CP1 patients, relapse and disease-free survival were similar across age cohorts. Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML, especially if still in CP1. (Blood. 2012;119(17):4083-4090)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据